News & Updates

Women with a dietary pattern contributing to hyperinsulinaemia and insulin resistance appear to be at increased risk of breast cancer, particularly estrogen-receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-enriched tumours, reveals a study.

The second-generation BTK* inhibitor zanubrutinib was superior to the standard-of-care ibrutinib in improving progression-free survival (PFS) among patients with relapsed/refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (SLL), according to results of the phase III ALPINE trial presented at ASH 2022.

The KRAS^G12C inhibitors, adagrasib and sotorasib, have shown promising antitumour activity in patients with heavily pretreated metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer, respectively.

Pancreatic cancer may be identified early if assessment will be steered towards the point of recent hyperglycaemia based on elevated HbA1c, suggests a retrospective cohort study, noting that such early detection may then improve survival in cancer patients.

Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.

The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.